Canada markets closed

BetterLife Pharma Inc. (BETRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0700-0.0021 (-2.87%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0721
Open0.0727
BidN/A x N/A
AskN/A x N/A
Day's Range0.0700 - 0.0727
52 Week Range0.0310 - 0.0940
Volume6,130
Avg. Volume36,200
Market Cap8.108M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University

    VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its development of 2-bromo-LSD was highlighted in Carleton University’s articled titled “Beyond the Magic of Mushrooms: Using Psychedelic Derivatives to Treat Depression”. The article discusses

  • GlobeNewswire

    BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001

    VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of $300,000 convertible debentures to further advance the development its lead compound, BETR-001. BETR-001 is BetterLife’s proprietary 2-bromo-LSD, a non-hallucinogenic derivative

  • GlobeNewswire

    BetterLife Announces Closing of a Private Placement

    VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private placement pursuant to which the Company issued 2,000,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $200,000 (the “Of